Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program

INTRODUCTION: In October 2015, the Food and Drug Administration (FDA) instituted an update to the mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine to improve safety monitoring of hematologic events. However, the impact of the clozapine REMS program on reporting of hemat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ment Health Clin
Main Authors: Borrelli, Eric P., Lee, Erica Y., Caffrey, Aisling R.
Formato: Artigo
Idioma:Inglês
Publicado em: College of Psychiatric & Neurologic Pharmacists 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213944/
https://ncbi.nlm.nih.gov/pubmed/32420002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9740/mhc.2020.05.070
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados